from eight managed care organizations. Index claims were outpatient or emergency department visits in 1999-2001 by individuals aged 25-64 with a primary diagnosis of pneumonia, antibiotic prescription within three-days, chest x-ray on index date, continuous enrollment for 12-months prior, 30-days after index visit. Exclusion criteria: antibiotic prescription, pneumonia diagnosis, or hospitalization in prior 30-days; initial therapy with multiple antibiotics; in prior 12-months residence in a long-term care facility or diagnosis of lung cancer, secondary malignancy, HIV/AIDS, cystic fibrosis, immunodeficiency. We considered the following comorbid illnesses: chronic liver, renal or lung disease; cerebrovascular disease; cardiac disease; diabetes mellitus; malignancy. Follow-up claims were considered CAP-related if the primary diagnosis, using the Clinical Classifications Software, was pneumonia; septicemia; pleurisy, pneumothorax or pulmonary collapse; respiratory failure, insufficiency or arrest; other lower respiratory infection. RESULTS: In total, 5748 cases met criteria; 79.7% had no comorbidities, 16.8% had one comorbidity, and 3.5% had two or more comorbidities. Mean total charges were $955.97: 48.2% inpatient, 25.2% outpatient, 13.4% outpatient testing and diagnostics, 7.5% antibiotic prescriptions, 5.8% emergency department, 13.9% presenting to the emergency department had initial mean charges of $360.48 compared with mean initial charges for outpatients of $167.89. In total, 50.0% utilized follow-up services with 3.0% requiring hospitalization. Mean total charges for those eventually hospitalized were $16,436.23 compared with $673.71 for the 13.1% of patients who failed initial treatment but were not hospitalized, and $431.91 for the 78.0% of patients requiring no additional antibiotics. Number of comorbidities was strongly associated (p < 0.0001) with charges: $888.19 for those without comorbidities vs. $1734.37 for those with multiple comorbidities. CONCLUSION: Cost of outpatient CAP for non-elderly adults is large even for those without comorbid illness. Patients with a potential cSSI were identified using the specific ICD-9 diagnosis codes. Costs of care and lengths of stay, based on the hospital's true cost accounting system, were compared by Diagnosis Related Group (DRG) between the cSSI population and the non-cSSI population. RESULTS: Of the 33,764 patient discharges in 2003, 1,883 (5.5%) included one of the cSSI diagnosis codes; these encompassed 225 DRGs. The mean cost for cSSI cases was $20,965 higher than for non-cSSI cases, and mean LOS was ten days higher for cSSI cases. For surgical and medical DRGs, mean cost of cSSI added $42,563 onto the cost for cases in surgical DRGs compared to an average increase of $10,048 added to cost of medical DRGs. Differences in costs and LOS were observed in analyses by Major Disease Categories (MDCs) and individual DRGs as well. For MDCs, myeloproliferative disorders, multiple trauma, and diseases of the nervous system, costs were $68,027, $48,286, and $27,496, higher for the cSSI cases, respectively. This difference was also reflected in additional days of stay of 22, 11, and 14 days, respectively. For patients with cSSI, the three specific DRGs responsible for the maximum total health care dollars expended were bone marrow transplants, rehabilitation, and small and large bowel procedures. CONCLUSIONS: cSSIs significantly increase hospital resource consumption and costs. The difference in costs is especially pronounced for patients undergoing surgical procedures. Results suggest that measures taken to avoid or more effectively treat cSSIs could yield significant savings to hospitals.
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PIN16 COST-UTILITY OF CHRONIC HEPATITIS "C" TREATMENT WITH THYMOSIN ALPHA 1 IN MEXICO
Nevárez-Sida A, García-Contreras F, Constantino-Casas P, Castro-Rios A, Mould J, Garduño-Espinosa J Mexican Institute of Social Security, Mexico City, Mexico OBJECTIVE: To estimate cost-utility of the following alternatives in the treatment of chronic hepatitis C (CHC) in the Mexican Institute of Social Security (IMSS): peginterferon, peginterferon plus ribavirin, peginterferon plus ribavirin plus thymosin alpha-1 and finally, not using any drug. METHODS: In Mexico, more that one million persons are infected with CHC virus and 80% of them develop chronic infection that might lead to hepatic cirrhosis and other complications that affect quality of life and costs of health care institutions. Cost-utility analysis was carried out using institutional perspective and time horizon of 45 years, discount rate of 3% for both, costs and effectiveness. The base case was a 30-year-old man with CHC without hepatic cirrhosis or cancer and cost and effectiveness data were taken from literature, a Mexican expert panel and an on-going clinical trial, not yet reported. Effectiveness data are reported in QALYs and costs in 2004 USD. A decision tree using a Bayesian approach and a Markov model were developed. Sensitivity analysis was univariate, bivariate, threshold and probabilistic. Acceptability curves and health net benefits were estimated. RESULTS: Triple therapy (peginterferon plus ribavirin plus thymosin alpha-1) was dominant over the rest of alternatives costing $1802 per QALY, while peginterferon plus ribavirin $2275 per QALY and peginterferon only $2927 per QALY. Not using any drug was the most costly alternative with $4201 per QALY. Sensitivity analysis confirmed the strength of the base study. Triple therapy was not dominated in any comparative case. CON-CLUSIONS: Triple therapy had the best cost-utility ratio and not using any drug was the opposite, most expensive and with less utility than all the compared alternatives. Although triple therapy is initially very expensive, it provides the highest gains in the long run, both in the improvement of quality of life and in saving costs.
PIN17 A COMPARISON OF METHODS TO ASSESS QUALITY OF LIFE IN ECONOMIC ANALYSES OF HEPATITIS C TREATMENTS
Yeh WS, Skrepnek GH, Armstrong EP, Malone DC University of Arizona College of Pharmacy, Tucson, AZ, USA OBJECTIVES: This study investigated the effect of using different utilities for a cost-utility analysis comparing peginterferon alpha-2b plus ribavirin, interferon alpha-2b plus ribavirin, and no treatment for chronic hepatitis C from a U.S. payer's perspective. METHODS: A Markov model was developed to simulate the lifetime disease progression of hepatitis C virus (HCV) for a 45-year-old male. The analysis was conducted by stratifying HCV genotypes. Health-state utilities were obtained from previously published literature. Standard gamble patient-elicited utilities were used as the base case. Five other expert-estimated utilities were compared to the patient-derived utilities. Treatment data, disease transition probabilities, and hepatitis C related costs were obtained from published literature. The costs of hepatitis C treatments were obtained from an Internet pharmacy. All costs were adjusted to 2004 USD. RESULTS: When patientreported utilities were used for HCV genotype 1, peginterferon gained 1.28 additional quality-adjusted life years (QALYs) compared with no treatment. The QALYs ranged from 0.71 to 2.35 when expert panel-estimated utilities were employed. For HCV genotype 2 or 3 patients, peginterferon group had 2.72 more QALYs than no treatment using patient-reported utilities. When expert panel utilities were used for genotype 2 or 3, peginterferon had 1.61 to 4.85 additional QALYs than no treatment. Using patient-derived utilities, the expected costs per QALY for HCV genotype 1 receiving peginterferon and interferon treatment were $2439 and $2335, respectively. For genotype 2 or 3, these costs were $1152 and $1085 per QALY, respectively. The lifetime HCV related cost for patients received no treatment was $1975 per QALY regardless of HCV genotype. CONCLUSION: Many expert panel-estimated utilities provided higher estimates of the benefits, and thus lower cost per QALY, for HCV treatments as compared to patient-reported utilities. 4 Bristol-Myers Squibb, Plainsboro, NJ, USA For patients with chronic hepatitis B, emergence of lamivudine resistance is associated with poor clinical outcomes, more rapid disease progression and poor quality of life. The clinical implications of lamivudune resistance are well described but the health care costs are not. OBJECTIVE: The objective of this study was to evaluate the health care utilization and direct medical cost within the first year of developing a lamivudine refractory infection in chronic hepatitis B (CHB) patients. METHODS: Physician estimates of health care utilization for the care of lamivudine refractory CHB patients were collected in a survey of physicians treating CHB patients in the US. A questionnaire was mailed to 165 physicians of which 51 responded. Data on health care utilization was computed for each health care cost category (Physician visits, hospitalizations, diagnostic tests and radiological examinations). Unit costs were derived based on the Medicare Physician Fee Schedule for procedures, the 2002 Health Care Cost and Utilization Project database for inpatient hospitalization costs, and average wholesale prices for medication costs. RESULTS: The total non-drug, direct medical cost within the first year of developing a lamivudine refractory infection in a CHB patient was estimated at $2925. Among the different cost categories diagnostic tests and specialist visits were the major cost drivers, accounting for an estimated 45% and 41% of the overall cost, respectively. Seventy four percent of the patients were estimated to require a specialist visit. Only 2% of patients were estimated to require a hospitalization accounting for a negligible proportion of the costs. CONCLU-SION: The estimated non-drug costs for patients refractory to lamivudine represent a substantial economic burden. In addition, the additional costs of rescue therapy further increase the cost impact and make it considerably higher than the annual direct medical cost for CHB patients who do not develop viral resistance. Several studies show that in developing countries, low-income patients use low price counterfeit drugs provided by the illegal drug market. In Cameroon, those false drugs represent 40% of the street market and lead to malaria therapeutic failure and inappropriate medical expenses. The Yaoundé program aims to improve access to efficient antimalarial drugs by providing a differentiated price policy through the official private pharmacy distribution sector,allowing access to efficient antimalarials to low-income population which would otherwise use street market drugs. METHODS: In 31 retail pharmacies of Yaoundé, artesunate (Arsumax®)was made available at a "no profit no loss" public price of 1170FCFA (1.78€) instead of 3400FCFA (5.8€), ie: -66%. Eligibility of patients was based on income below the poverty level (established by the Ministry of Economy as 30€ monthly households incomes per number of dependences).Program effectiveness was assessed by evaluating the number of new patients having access to this lower price Arsumax®. RESULTS: After 6 months of implementation,
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